Radium-223 dichloride (Benefits)
- Targeted Treatment: Xofigo’s ability to target bone metastases specifically reduces tumor burden in the bone, which can help alleviate pain and other symptoms associated with bone metastases.
- Survival Benefit: Clinical trials have shown that Xofigo can extend overall survival and improve the quality of life for patients with mCRPC.